{
  "table_name": "PURITY_PLOIDY_ALL_SAMPLES_FILTERED",
  "table_fullname": "PANCANCER_ATLAS_1.PANCANCER_ATLAS_FILTERED.PURITY_PLOIDY_ALL_SAMPLES_FILTERED",
  "column_names": [
    "Reinheit",
    "Studie",
    "Cancer_DNA_fraction",
    "CallStatus",
    "SampleBarcode",
    "ParticipantBarcode",
    "SampleTypeLetterCode",
    "Subclonal_genome_fraction",
    "Genome_doublings",
    "Ploidy",
    "Lösung",
    "SampleType",
    "AliquotBarcode",
    "Coverage_for_80_power"
  ],
  "column_types": [
    "FLOAT",
    "TEXT",
    "FLOAT",
    "TEXT",
    "TEXT",
    "TEXT",
    "TEXT",
    "FLOAT",
    "FLOAT",
    "FLOAT",
    "TEXT",
    "TEXT",
    "TEXT",
    "FLOAT"
  ],
  "description": [
    "Schätzungen der Reinheit; Werte zwischen 0 und 1, die den Bruchteil der Krebszellen in einer festen Tumorgewebsprobe darstellen",
    "TCGA-Studienabkürzung, z. B. LAML. Vollständige Liste verfügbar unter https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/tcga-study-abbreviations",
    "Krebs-DNA-Anteile; weitere Informationen verfügbar unter https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383288/",
    "Entweder 'called' oder NULL, um anzuzeigen, ob Daten analysiert wurden oder nicht",
    "Barcode der Biospecimen-Probe, z. B. TCGA-13-1489-02A",
    "TCGA-Barcode-Identifikator für den Studienteilnehmer, z. B. TCGA-02-0001",
    "Buchstabencode des ProbenTyps unter Verwendung der TCGA-Standards, z. B. TPN, EBV. Vollständige Liste verfügbar unter https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/sample-type-codes",
    "Subklonale Genome-Anteile; weitere Informationen verfügbar unter https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383288/",
    "Anzahl der ganzen Genome-Verdopplungen",
    "Wert basierend auf dem DNA-Gehalt der Tumorzellpopulation im Vergleich zu normalen Diploidzellen",
    "'Neu' oder 'alt' Berechnungen/Lösungen",
    "Es gibt 10 ProbenTypen: Blutabgeleitete Normale, Primärer fester Tumor, Fester Gewebenorm, Rezidivierender fester Tumor, Metastatischer, Zusätzlicher - Neuer Primär, Primärer Blutabgeleiteter Krebs - Peripheres Blut, Buccalzellen-Norm, Zusätzlicher Metastatischer, Knochenmark-Norm",
    "TCGA-Aliquot-Barcode, z. B. TCGA-12-1089-01A-01D-0517-28",
    "Durchschnittliche Abdeckung, die notwendig ist, um 80 % Power in 80 % des Genoms zu erhalten"
  ],
  "sample_rows": [
    {
      "AliquotBarcode": "TCGA-AB-2879-03A-01D-0756-21",
      "ParticipantBarcode": "TCGA-AB-2879",
      "SampleBarcode": "TCGA-AB-2879-03A",
      "CallStatus": "called",
      "Reinheit": 0.25,
      "Ploidy": 2.0,
      "Genome_doublings": 0.0,
      "Coverage_for_80_power": 43.0,
      "Cancer_DNA_fraction": 0.25,
      "Subclonal_genome_fraction": 0.0,
      "Lösung": "new",
      "Studie": "LAML",
      "SampleTypeLetterCode": "TB",
      "SampleType": "Primary Blood Derived Cancer - Peripheral Blood"
    },
    {
      "AliquotBarcode": "TCGA-ZC-AAAH-01A-11D-A427-01",
      "ParticipantBarcode": "TCGA-ZC-AAAH",
      "SampleBarcode": "TCGA-ZC-AAAH-01A",
      "CallStatus": "called",
      "Reinheit": 0.25,
      "Ploidy": 2.0,
      "Genome_doublings": 0.0,
      "Coverage_for_80_power": 43.0,
      "Cancer_DNA_fraction": 0.25,
      "Subclonal_genome_fraction": 0.09,
      "Lösung": "new",
      "Studie": "THYM",
      "SampleTypeLetterCode": "TP",
      "SampleType": "Primary solid Tumor"
    },
    {
      "AliquotBarcode": "TCGA-44-3396-01A-01D-1204-01",
      "ParticipantBarcode": "TCGA-44-3396",
      "SampleBarcode": "TCGA-44-3396-01A",
      "CallStatus": "called",
      "Reinheit": 0.24,
      "Ploidy": 2.13,
      "Genome_doublings": 0.0,
      "Coverage_for_80_power": 45.0,
      "Cancer_DNA_fraction": 0.25,
      "Subclonal_genome_fraction": 0.16,
      "Lösung": "new",
      "Studie": "LUAD",
      "SampleTypeLetterCode": "TP",
      "SampleType": "Primary solid Tumor"
    },
    {
      "AliquotBarcode": "TCGA-2K-A9WE-01A-11D-A381-01",
      "ParticipantBarcode": "TCGA-2K-A9WE",
      "SampleBarcode": "TCGA-2K-A9WE-01A",
      "CallStatus": "called",
      "Reinheit": 0.22,
      "Ploidy": 2.38,
      "Genome_doublings": 0.0,
      "Coverage_for_80_power": 52.0,
      "Cancer_DNA_fraction": 0.25,
      "Subclonal_genome_fraction": 0.11,
      "Lösung": "new",
      "Studie": "KIRP",
      "SampleTypeLetterCode": "TP",
      "SampleType": "Primary solid Tumor"
    },
    {
      "AliquotBarcode": "TCGA-49-AAQV-01A-11D-A396-01",
      "ParticipantBarcode": "TCGA-49-AAQV",
      "SampleBarcode": "TCGA-49-AAQV-01A",
      "CallStatus": "called",
      "Reinheit": 0.25,
      "Ploidy": 1.94,
      "Genome_doublings": 0.0,
      "Coverage_for_80_power": 41.0,
      "Cancer_DNA_fraction": 0.25,
      "Subclonal_genome_fraction": 0.43,
      "Lösung": "new",
      "Studie": "LUAD",
      "SampleTypeLetterCode": "TP",
      "SampleType": "Primary solid Tumor"
    }
  ]
}